Immunofluorescent assays in Figure 7 were independently performed in these CDK2, CDK9 or empty vector (EV)-transfected lung cancer cells following treatment with CYC065 (500 nM) or DMSO as a vehicle control. This evidence concerns the gene CDK9 and lung cancer.